---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-346908"
form_type: "8-K"
ticker: "TRAX"
cik: "0002091349"
company_name: "First Tracks Biotherapeutics, Inc."
filed_at: "2026-08-12T20:19:20+00:00"
generated_at: "2026-08-12T20:20:07.055831+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# First Tracks Q2 net loss $33.4M, cash $168M; ANB033 Fast Track, Cohort 1 data Q4

## Summary
- Q2 2026 net loss $33.4M ($0.95/share) vs $42.4M ($1.47) year-ago; R&D spend $25.6M.
- FDA granted Fast Track designation for ANB033 in celiac disease; Cohort 1 (n=30) fully enrolled, data Q4 2026.
- Cohort 2 expanded to up to 40 patients; top-line data expected Q1 2027; EoE Phase 1b data Q3 2027.
- Cash and investments $168.0M as of June 30, 2026; runway into Q2 2028.
- Planning Phase 2 trials in two additional indications in H1 2027.

## SEC filing metadata
- accession: 0001193125-26-346908
- form_type: 8-K
- ticker: TRAX
- cik: 0002091349
- company_name: First Tracks Biotherapeutics, Inc.
- filed_at: 2026-08-12T20:19:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/0001193125-26-346908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/trax-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-346908
- JSON: https://secwatch.observer/filing/0001193125-26-346908.json
- Plain text: https://secwatch.observer/filing/0001193125-26-346908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.